ClinicalTrials.gg
RecruitingNCT05169112Updated Mar 20, 2025

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

A Phase 3 interventional study of Lupron Depot in Prostate Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 3 sites in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Ottawa Hospital Research Institute · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Planned enrollment
38th of 69
72 · median 77
Started
2023
with 2 others
Phase 3
26 of 70
3 open now
Primary completion
2026-11
later than 4 of 15 live
Registered
54th of 70
by date

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 38th largest by planned enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2023, is one of 26 in phase 3, reaches primary completion later than 4 of the 15 other live ones, and was the 54th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation after recurrence is successful in less than half of these men and most of those die from their disease. Measures to prevent recurrence are an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. undetectable PSA (\<0.02 ng/ml) within 16 weeks post-operative;
  2. ≥25% predicted risk of PSA recurrence within 5 years of surgery (based on the Kattan nomogram)

Exclusion criteria

Exclusion Criteria:

  1. Unwilling to receive ADT;
  2. previously received ADT;
  3. lymph node
  4. allergy to any form of ADT
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    Standard of Care

  • Experimental
    Standard of Care plus Androgen Deprivation Therapy (Lupron Depot)

    22.5 mg intra-muscular injection of Lupron Depot every 3 months for 12 months (4 injections total)

    Drug: Lupron Depot

Interventions

  • DrugLeuprolideStudies of LeuprolideLeuprolide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months

06

What researchers measure

Primary outcomes

  1. Rate of enrolment

    Rate (patients/month) of enrolment

    Time frame: 1 year

Secondary outcomes

  1. Rate of enrolment per site

    Rate (patients/month) of enrolment per site

    Time frame: 1 year

  2. Proportion of patients completing study intervention per-protocol

    Proportion of patients completing study intervention per-protocol

    Time frame: 1 year

  3. Time to study start-up

    Time to study start-up at each site

    Time frame: 1 year

  4. Completeness of study assessments

    Proportion of study assessments completed per-protocol

    Time frame: 1 year

07

Study locations

2 of 3 sites recruiting
  • Nova Scotia Health
    Halifax, Nova Scotia B3H 2Y9, Canada
    Recruiting
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
  • Centre universitaire de santé McGill - McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No — N/A. IPD not planned to be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Nov 2026, 44 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 44 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2021
First posted
Dec 23, 2021
StartActual
Mar 6, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2028
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05169112
Collaborators
Tolmar Pharmaceuticals
Responsible party
Rodney Breau (Dr., Ottawa Hospital Research Institute) — Principal investigator
First posted
Dec 23, 2021
Start date
Mar 6, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2028 (estimated)
Last update
Mar 20, 2025

Study contacts

Rodney Breau, Dr.
Contact
rbreau@toh.on.ca
613-737-8899 ext. 73019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion